Welcome to our dedicated page for Protara Therapeutics SEC filings (Ticker: TARA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Protara Therapeutics, Inc. filings document a Nasdaq-listed, Delaware clinical-stage biotechnology company developing TARA-002 for non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride for patients receiving parenteral support. Form 8-K disclosures include clinical-data updates, Regulation FD materials, financial results, investor presentations, and business updates related to the company's investigational programs.
The filing record also covers Protara's capital structure and governance, including common stock registered on The Nasdaq Global Market, public offering and underwriting agreements, warrant-related disclosures, and proxy materials for annual stockholder voting. Proxy filings describe board elections, executive compensation matters, equity plans, audit oversight, and other corporate-governance proposals.
Janus Henderson Group plc reports beneficial ownership of 5,207,011 shares of Protara Therapeutics, Inc. common stock, representing 9.6% of the class. The holdings are reported on behalf of multiple investment advisers that exercise shared voting and dispositive power for managed portfolios.
The filing notes that the Managed Portfolios generally exercise investment and voting discretion but do not have rights to receive dividends or sale proceeds; the Janus Henderson Biotech Innovation Master Fund Ltd. holds the right to receive dividends or proceeds for more than 5% of the class. The amendment is signed on 5/15/2026.
Protara Therapeutics, Inc. has registered a shelf to offer up to $300,000,000 of common stock, preferred stock, debt securities and/or warrants.
The prospectus states the registration includes $110,914,137.87 of unsold securities from a prior registration and that specific terms and proceeds treatment will be set forth in future prospectus supplements. The company notes its Nasdaq symbol is TARA and that its common stock last traded at $5.27 per share on May 11, 2026. The filing reiterates that proceeds will be used for general corporate purposes, including research and development, clinical trials and working capital.
Protara Therapeutics reported a wider net loss for the three months ended March 31, 2026 as it accelerated investment in its pipeline. Net loss was $17.8 million versus $11.9 million a year earlier, driven by higher research and development spending of $13.6 million and general and administrative costs of $6.1 million.
The company ended the quarter with $177.4 million in unrestricted cash, cash equivalents and marketable debt securities and believes this will fund operations for at least 12 months. Protara advanced multiple programs, including TARA-002 for non-muscle invasive bladder cancer with promising complete response rates, TARA-002 for pediatric lymphatic malformations with interim clinical success in STARBORN-1, and initiated the registrational THRIVE-3 Phase 3 trial for IV Choline Chloride in long-term parenteral support patients.
Protara Therapeutics reported a larger net loss as it advances its pipeline. For the quarter ended March 31, 2026, the company recorded a net loss of $17.8 million, compared with $11.9 million a year earlier, driven by higher research and development and general and administrative expenses.
Research and development spending rose to $13.6 million, while general and administrative costs were $6.1 million. Protara ended the quarter with cash, cash equivalents and investments of approximately $177 million, which it expects will fund operations into 2028.
Clinically, the company plans to submit a Biologics License Application for TARA‑002 in lymphatic malformations in the second half of 2027, and aims to complete enrollment of the BCG‑unresponsive registrational cohort of the ADVANCED‑2 bladder cancer trial and start the ADVANCED‑3 registrational trial in BCG‑naïve patients in the second half of 2026. It also expects multiple data readouts in 2026, including interim TARA‑002 data and interim THRIVE‑3 IV Choline Chloride results.
Protara Therapeutics, Inc. is asking stockholders to vote on seven proposals at its virtual 2026 annual meeting on June 12, 2026. Items include electing three Class III directors, ratifying Ernst & Young LLP as auditor, and advisory votes on executive pay and its frequency.
Stockholders will also consider an amendment to the 2024 Equity Incentive Plan and two charter amendments: one to increase authorized common shares from 100,000,000 to 200,000,000, and another to add officer exculpation as permitted by Delaware law. A record 55,060,500 common shares are entitled to vote as of April 15, 2026.
Protara Therapeutics reports that BlackRock, Inc. beneficially owns 3,387,459 shares of Common Stock, representing 6.3% of the class as of 03/31/2026. The filing states BlackRock has sole voting power for 3,347,945 shares and sole dispositive power for 3,387,459 shares. The schedule notes various persons may have rights to dividends or sale proceeds and is signed by a BlackRock Managing Director on 04/27/2026.
Affiliate reported proposed sales of Common Stock under Rule 144. The filing lists multiple entries by Baker Brothers Life Sciences, L.P. showing reported sale activity on 02/24/2026, 02/25/2026, 03/04/2026, and 03/06/2026 with associated numeric entries in the filing. The record also lists Jefferies LLC as an underwriter reference and an earlier underwriting date of 09/22/2020.
TARA filed a Form 144 notice reporting proposed sales of Common Stock by an affiliate/insider. The filing lists multiple proposed dispositions in late February and early March 2026, including specific lots: 26,755 shares on 02/24/2026, 78,716 shares on 02/25/2026, 35,173 shares on 03/04/2026, and 38,277 shares on 03/06/2026. The filing names Jefferies LLC as underwriter in connection with the securities to be sold.
Protara Therapeutics, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held virtually on June 12, 2026 at 12:00 p.m. Eastern Time. The Record Date is April 15, 2026 and 55,060,500 shares of common stock were outstanding on that date.
Stockholders will vote on seven proposals including election of three Class III directors, ratification of Ernst & Young LLP as auditor, advisory votes on executive compensation and frequency, amendment of the 2024 Equity Incentive Plan, an amendment to increase authorized common shares from 100,000,000 to 200,000,000, and an amendment to allow officer exculpation under Delaware law. The proxy statement explains voting procedures, broker non-votes, quorum rules and how to access proxy materials online.